Novo and Lilly Present GLP-1 Anti-Aging Data at Harvard ARDD, Claiming 1.1 Years Younger in 72 Weeks

At the 2026 Harvard ARDD meeting, Novo Nordisk and Eli Lilly presented unpublished clinical data positioning GLP-1 receptor agonists as longevity drugs, moving beyond the open question raised at the 2023 meeting. A presented conclusion was that semaglutide and other GLP-1 receptor agonists may support healthier aging, with evidence spanning survival, physical function and a class effect. A headline claim was 1.1 years of biological age reduction over 72 weeks.